300142 Walvax Biotechnology
- 14.19
- -0.30-2.07%
Walvax Biotechnology News
Watson Biotech (300142.SZ): The phase III clinical trial comparing the immunogenicity of the nine-valent HPV vaccine and similar vaccines is currently in the stage of statistical data analysis and writing clinical research reports
GLONGHUI May 14 | Watson Biotech (300142.SZ) held a performance briefing on May 13, 2024 to discuss “When will the nine-cost head-to-head data report on human cancer be released? Is there a time limit?” The company replied that the phase III clinical trial comparing the immunogenicity of the company's nine-valent HPV vaccine and similar vaccines is currently in the stage of statistical data analysis and writing clinical research reports. Please continue to pay attention to the company's information disclosure on related developments.
Watson Biotech (300142.SZ): Some of the company's vaccine products involve synthetic biology-related technology in the development and production process
Gelonghui, May 9 | Watson Biotech (300142.SZ) said on the investor interactive platform that some of the company's vaccine products involved synthetic biology-related technology in the development and production process.
Walvax Biotechnology Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Walvax Biotechnology Co., Ltd. (SZSE:300142) missed earnings with its latest first-quarter results, disappointing overly-optimistic forecasters. The analysts look to have been far too optimistic
Watson Biotech (300142.SZ): Quarterly report to be disclosed on April 25
Gelonghui, April 23 | Watson Biotech (300142.SZ) said on the investor interactive platform that the company will disclose the 2024 quarterly report on April 25, 2024. For specific operating data, please refer to the regular report disclosed later.
Watson Biotech (300142.SZ): Currently, the company's RQ3033 vaccine is actively applying for approval for marketing
Gelonghui, April 18 | Watson Biotech (300142.SZ) said on the investor interactive platform that currently the company's RQ3033 vaccine is actively applying for approval for listing (including conditional listing), but the exact timing is subject to regulatory approval. The company continues to monitor the mutation of the coronavirus strain and promotes the development of iterative products through immunogenic bridging and other methods in accordance with the overall deployment of the country. If approved for listing in the future (including conditional listing), it is expected to have a positive impact on the company's business performance.
Investors Can Find Comfort In Walvax Biotechnology's (SZSE:300142) Earnings Quality
The market for Walvax Biotechnology Co., Ltd.'s (SZSE:300142) shares didn't move much after it posted weak earnings recently. We think that the softer headline numbers might be getting counterbalance
Watson Biotech (300142.SZ): The repurchase was completed and the total cost was 72.197,800 yuan to repurchase 2 million shares
Gelonghui, April 3, 丨 Watson Biotech (300142.SZ) announced that the actual time period for the company to repurchase shares is from April 7, 2023 to April 3, 2024. As of April 3, 2024, the total number of shares repurchased by the company through centralized bidding transactions through a dedicated securities account was 2 million shares, accounting for 0.12% of the company's total share capital. The highest transaction price was 36.28 yuan/share, the lowest transaction price was 35.69 yuan/share, and the total transaction amount was 72.1978 million yuan (excluding transaction fees). The implementation of this share repurchase plan has been completed.
Watson Biotech (300142.SZ): Currently, the 13-valent pneumonia conjugate vaccine has been vaccinated in four countries including Morocco
On April 3, GLONGHUI | Watson Biotech (300142.SZ) said on the investor interactive platform that the company's 13-valent pneumonia conjugate vaccine has now been vaccinated in four countries: Morocco, Thailand, Bangladesh and Indonesia.
Watson Bio (300142.SZ): There is currently no adult pertussis vaccine
On April 3, GLONGHUI | Watson Biotech (300142.SZ) said on the investor interactive platform that the company's adsorbed acell-free DPT vaccine is suitable for children aged 3 months to 5 years, and there is currently no adult pertussis vaccine.
Walvax Biotechnology Co., Ltd. (SZSE:300142) Just Reported And Analysts Have Been Cutting Their Estimates
Walvax Biotechnology Co., Ltd. (SZSE:300142) came out with its yearly results last week, and we wanted to see how the business is performing and what industry forecasters think of the company followin
Walvax Biotechnology Scraps Plan to Issue Convertible Bonds
Walvax Biotechnology (SHE:300142) withdrew its plan to list convertible corporate bonds on the Shenzhen Stock Exchange, the company said in a filing with the Shenzhen bourse on Saturday. The Chinese b
Watson Biotech (300142.SZ) announced 2023 annual results, net profit of 419 million yuan, a decrease of 42.44%
According to the Zhitong Finance App, Watson Biotech (300142.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 4.114 billion yuan, a year-on-year decrease of 19.12%. Achieved net profit attributable to shareholders of listed companies of 419 million yuan, a year-on-year decrease of 42.44%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 574 million yuan, a year-on-year decrease of 33.95%. Basic earnings per share were $0.2621. It is proposed to distribute a cash dividend of 0.10 yuan (tax included) for every 10 shares to all shareholders. The company's autonomous vaccine production will increase in 2023
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Watson Biotech (300142.SZ): Has repurchased a total of 2 million shares
Glonghui, March 1 | Watson Biotech (300142.SZ) announced that as of February 29, 2024, the stock repurchase company had repurchased 2 million shares through a dedicated securities account, accounting for 0.12% of the company's total share capital. The highest transaction price was 36.28 yuan/share, the minimum transaction price was 35.69 yuan/share, and the total transaction amount was 72,197,766.44 yuan (excluding transaction fees).
Declining Stock and Decent Financials: Is The Market Wrong About Walvax Biotechnology Co., Ltd. (SZSE:300142)?
With its stock down 24% over the past three months, it is easy to disregard Walvax Biotechnology (SZSE:300142). But if you pay close attention, you might find that its key financial indicators look
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit
Walvax Biotechnology (SHE:300142) expects to record a 37% to 45% year-over-year drop in net profit in 2023, which the company attributed to market challenges. Net profit is forecast to have fallen to
Watson Biotech (300142.SZ): Does not involve veterinary vaccines
GLONGHUI January 23 | Watson Biotech (300142.SZ) said on the investor interactive platform that the company's vaccine products already on the market are all human vaccines and do not involve veterinary vaccines.
23% Earnings Growth Over 1 Year Has Not Materialized Into Gains for Walvax Biotechnology (SZSE:300142) Shareholders Over That Period
Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Walvax Biotechnology Co., Ltd. (SZSE:300142) have suffered share price declines over the last ye
Watson Biotech (300142.SZ): There is currently no quadrivalent influenza virus lysis vaccine under development
Gelonghui, January 15 | Watson Biotech (300142.SZ) said on the investor interactive platform that the company has transferred all of Jiangsu Watson's shares in 2022, and there is currently no quadrivalent influenza virus lysis vaccine under development.
Watson Biology (300142.SZ): The nine-valent HPV vaccine is undergoing serological testing in a phase III clinical trial comparing immunogenicity with Gardasil9
GLONGHUI December 26 丨 An investor asked Watson Biotech (300142.SZ) on the investor interactive platform, “Is the company's nine-valent HPV vaccine being developed, and is it aimed at promoting marketing?” The company replied that the company's nine-valent HPV vaccine is undergoing serum testing for phase III clinical trials comparing immunogenicity with Gardasil9. Once immunogenicity results are obtained, clinical trials necessary to apply for marketing will be carried out in accordance with the latest regulatory requirements. Please refer to the company's announcement for further progress.
Analysis
Price Target
No Data
